In this free webinar, learn the importance of multiplex testing for respiratory symptoms. Attendees will learn the importance of delineating viral and bacterial causes of respiratory illness. The featured speaker will discuss the impact of undiagnosed respiratory disease on the hospital.
TORONTO, April 21, 2022 /PRNewswire-PRWeb/ -- Join featured speaker Dr. Jennifer Dien Bard as she examines respiratory illness from a symptomatic perspective. Dr. Dien Bard will focus on the diagnostic importance of adopting a comprehensive approach to the patient, inclusive of history, physical exam and a multiplex laboratory assay. Register now to explore the impact of multiplex testing and secure a spot at this educational, meaningful and impactful event.
Surges in influenza-like illness testing during respiratory season have always impacted both clinical and laboratory environments. But the unique challenges presented during the COVID-19 pandemic have forced a paradigm shift in the way respiratory diseases are diagnosed and managed. Focus has moved away from influenza testing alone to a broader group of potential causative pathogens, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Once COVID-19 enters its endemic phase, a comprehensive approach to laboratory medicine and patient management will likely become crucial. While recent assumptions about respiratory symptomatology have been directed toward SARS-CoV-2 based on prevalence data, other respiratory pathogens are once again on the rise. Seasonality of respiratory pathogens has also shifted as evidenced by summer-time surges of respiratory syncytial virus (RSV) and human metapneumovirus.
While a patient's history and physical exam alone may reflect common causes, a molecular diagnostic tool that targets multiple potential causative pathogens can support efficient patient management. Diagnostic accuracy not only benefits the patient, but also supports laboratories in their outreach to clinician offices, hospitals that routinely work to ensure treatment paradigms are precise and clinicians who seek to provide timely treatments to maximize patient satisfaction.
In this webinar, attendees will learn about the impact of multiplex testing for respiratory disease in North America on the laboratorian, the clinician and the patient. Attendees will also learn how a symptoms-based approach can support optimal outcomes for all the aforementioned stakeholders, and how those outcomes may differ with the inclusion (or exclusion) of a diagnostic tool for common viral and bacterial pathogens.
Join Dr. Jennifer Dien Bard, Associate Professor of Pathology, Keck School of Medicine, for the live webinar on Wednesday, May 11, 2022, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit The Impact of Multiplex Testing for Respiratory Infections in North America.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article